Augusto Villanueva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8897328/publications.pdf

Version: 2024-02-01

144 papers	28,029 citations	13865 67 h-index	9103 144 g-index
155 all docs	155 docs citations	155 times ranked	24638 citing authors

#	Article	IF	Citations
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	12.1	90
2	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	12.1	42
3	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	12.1	24
4	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. Talanta, 2022, 241, 123256.	5.5	12
5	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology, 2022, 16, 665-682.	4.6	3
6	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305.	7.0	8
7	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	13.2	126
8	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	3.6	6
9	DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology, 2021, 74, 183-199.	7.3	42
10	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	7.3	235
11	Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127.	7.3	104
12	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151.	5.9	77
13	Signaling pathways in hepatocellular carcinoma. Advances in Cancer Research, 2021, 149, 63-101.	5.0	56
14	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers, 2021, 13, 659.	3.7	25
15	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Cloneâ€Dependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	4.3	7
16	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	3.5	15
17	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Reports, 2021, 3, 100237.	4.9	32
18	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	1.3	91

#	Article	IF	Citations
19	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. Engineering, 2021, 7, 1369-1369.	6.7	1
20	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€"2020). Gastroenterology, 2021, 161, 879-898.	1.3	123
21	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Reports, 2021, 3, 100364.	4.9	9
22	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	30.5	2,757
23	Tumour evolution in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 139-152.	17.8	501
24	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Medicine, 2020, 18, 200.	5.5	25
25	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	12.1	77
26	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. Scientific Reports, 2020, 10, 5062.	3.3	5
27	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 73, 315-327.	3.7	164
28	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831.	2.4	25
29	Intratumoral heterogeneity and clonal evolution in liver cancer. Nature Communications, 2020, 11, 291.	12.8	230
30	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	12.1	195
31	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 2019, 121, 340-343.	6.4	62
32	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.9	99
33	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 62-65.	2.1	21
34	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology, 2019, 74, 718-730.	2.9	9
35	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	4.1	16
36	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Reports, 2019, 1, 120-130.	4.9	43

#	Article	IF	Citations
37	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€"PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	9.4	498
38	Mitohormesis Primes Tumor Invasion and Metastasis. Cell Reports, 2019, 27, 2292-2303.e6.	6.4	69
39	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology, 2019, 70, 2107-2122.	7.3	26
40	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Research, 2019, 21, 56.	5.0	19
41	Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462.	27.0	2,966
42	The Impact of Translational Research in Hepatology. Clinical Liver Disease, 2019, 13, 29-33.	2.1	2
43	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	3.7	150
44	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	5.9	89
45	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience, 2018, 5, 209-211.	2.2	11
46	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Scientific Reports, 2018, 8, 11570.	3.3	64
47	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66, 530-540.	12.1	161
48	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. Journal of Hepatology, 2017, 66, 952-961.	3.7	120
49	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	1.3	650
50	Liver Cancer Cell of Origin, Molecular Class, and Effects onÂPatient Prognosis. Gastroenterology, 2017, 152, 745-761.	1.3	838
51	Divergent evolutionary trajectories in transplanted tumor models. Nature Genetics, 2017, 49, 1565-1566.	21.4	13
52	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 1222-1231.	3.7	121
53	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. Current Clinical Pathology, 2017, , 125-135.	0.0	3
54	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. Journal of Hepatology, 2017, 67, 893-895.	3.7	4

#	Article	IF	Citations
55	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-24.	0.1	0
56	Molecular profiling of liver cancer heterogeneity. Discovery Medicine, 2017, 24, 117-125.	0.5	3
57	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver diseaseâ€hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 2016, 8, 100-104.	2.1	20
58	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	16.8	172
59	The transition from inflammation to cancer in the liver. Clinical Liver Disease, 2016, 8, 89-93.	2.1	25
60	Selected summary for the 2015 Asiaâ€"Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepatic Oncology, 2016, 3, 5-8.	4.2	0
61	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
62	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	1.3	103
63	Effect of HCV clearance with direct-acting antiviral agents on HCC. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 561-562.	17.8	67
64	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	3.7	219
65	Liver capsule: Molecularâ€based signatures in hepatocellular carcinoma. Hepatology, 2016, 63, 2018-2018.	7.3	9
66	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	12.1	108
67	Circulating tumor cells and cholangiocarcinoma. Hepatology, 2016, 63, 23-25.	7.3	4
68	Clinical Trial Watch: Reports from the Liver MeetingÂ®, AASLD, San Francisco, November 2015. Journal of Hepatology, 2016, 64, 1428-1445.	3.7	3
69	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	27.6	456
70	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	7.3	367
71	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	1.3	109
72	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	1.3	980

#	Article	IF	Citations
73	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. Journal of Hepatology, 2015, 63, 753-762.	3.7	5
74	DNA-PKâ€"A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research, 2015, 21, 925-933.	7.0	74
75	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	21.4	1,372
76	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. Clinical Cancer Research, 2015, 21, 1786-1788.	7.0	73
77	The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics, 2015, 16, 1671-1683.	1.3	43
78	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
79	The usual SASPects of liver cancer. Aging, 2015, 7, 348-349.	3.1	4
80	Liquid biopsy in liver cancer. Discovery Medicine, 2015, 19, 263-73.	0.5	40
81	Transplantation for hepatocellular carcinoma-worth waiting for?. Liver Transplantation, 2014, 20, 871-873.	2.4	1
82	Mutational landscape of HCCâ€"the end of the beginning. Nature Reviews Clinical Oncology, 2014, 11, 73-74.	27.6	108
83	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 196-209.	16.8	261
84	VEGF Signaling in Cancer Treatment. Current Pharmaceutical Design, 2014, 20, 2834-2842.	1.9	74
85	Prognostic Gene Expression Signature for Patients With Hepatitis Câ€"Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
86	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated withEGFR. Hepatology, 2013, 57, 120-130.	7.3	52
87	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. Journal of Hepatology, 2013, 59, 392-395.	3.7	20
88	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroenterology, 2013, 144, 829-840.	1.3	438
89	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 34-42.	17.8	277
90	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	1.3	302

#	Article	IF	Citations
91	Genetically engineered mouse models: future tools to predict clinical trial results in oncology?. Future Oncology, 2013, 9, 767-770.	2.4	1
92	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World Journal of Gastroenterology, 2013, 19, 1193.	3.3	34
93	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology, 2012, 56, 2416-2419.	7.3	16
94	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research, 2012, 18, 4997-5007.	7.0	251
95	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1198-1200.	3.7	3
96	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. Journal of Hepatology, 2012, 57, 213-214.	3.7	6
97	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 2012, 56, 1343-1350.	3.7	181
98	Why men are at higher risk for hepatocellular carcinoma?. Journal of Hepatology, 2012, 57, 453-454.	3.7	38
99	microRNAs: New ways to block tumor angiogenesis?. Journal of Hepatology, 2012, 57, 490-491.	3.7	9
100	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. Clinical Cancer Research, 2012, 18, 1824-1826.	7.0	86
101	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56, 1361-1370.	7.3	31
102	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology, 2012, 143, 1660-1669.e7.	1.3	262
103	Emerging Signaling Pathways in Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 83-93.	7.7	169
104	Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 473-485.	2.2	68
105	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1501-1512.e2.	1.3	389
106	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 2011, 140, 1618-1628.e16.	1.3	205
107	Hepatocellular Carcinoma Enters the Sequencing Era. Gastroenterology, 2011, 141, 1943-1945.	1.3	5
108	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	1.3	408

#	Article	IF	Citations
109	Signaling Pathways in Hepatocellular Carcinoma. Oncology, 2011, 81, 18-23.	1.9	39
110	Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1325-1331.	3.7	133
111	Depicting the role of TP53 in hepatocellular carcinoma progression. Journal of Hepatology, 2011, 55, 724-725.	3.7	54
112	Molecular Pathogenesis of Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2011, 35, 821-825.	2.4	47
113	Carcinogen-induced hepatic tumors in KLF6+/â^' mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology, 2011, 54, 522-531.	7.3	39
114	Inherited hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 725-734.	2.4	28
115	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. Clinical Cancer Research, 2010, 16, 4688-4694.	7.0	114
116	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Seminars in Liver Disease, 2010, 30, 035-051.	3.6	267
117	miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 1202-1204.	1.3	13
118	Cancer gene discovery in hepatocellular carcinoma. Journal of Hepatology, 2010, 52, 921-929.	3.7	173
119	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Journal of Hepatology, 2010, 52, 550-559.	3.7	211
120	Genomic tracing of the elusive liver cancer ancestor. Journal of Hepatology, 2010, 53, 578-579.	3.7	1
121	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	12.2	229
122	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009, 69, 7385-7392.	0.9	978
123	Lymphotoxins: New Targets for Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 272-273.	16.8	17
124	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nature Biotechnology, 2009, 27, 264-274.	17.5	194
125	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	3.7	206
126	Molecular profiling to predict hepatocellular carcinoma outcome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 101-103.	3.0	37

#	Article	IF	Citations
127	Pathogenesis of hepatocellular carcinoma and molecular therapies. Current Opinion in Gastroenterology, 2009, 25, 186-194.	2.3	118
128	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. Journal of Clinical Investigation, 2009, 119, 465-477.	8.2	298
129	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1521-1531.	1.3	96
130	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	1.3	644
131	Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.9	589
132	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	3.7	203
133	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. Journal of Hepatology, 2008, 49, 1-5.	3.7	35
134	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 2008, 7, 3129-3140.	4.1	1,237
135	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	27.0	1,148
136	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology, 2008, 20, 444-453.	2.4	60
137	Genomics and Signaling Pathways in Hepatocellular Carcinoma. Seminars in Liver Disease, 2007, 27, 055-076.	3.6	491
138	Current management of liver cancer. European Journal of Cancer, Supplement, 2007, 5, 444-446.	2.2	4
139	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	1.3	379
140	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. European Journal of Gastroenterology and Hepatology, 2006, 18, 79-83.	1.6	20
141	Systematic review: evidenceâ€based management of hepatocellular carcinoma â€“ an updated analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics, 2006, 23, 1535-1547.	3.7	341
142	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. Liver Transplantation, 2006, 12, 1747-1754.	2.4	16
143	Safety of Percutaneous Ethanol Injection as Neoadjuvant Therapy for Hepatocellular Carcinoma in Waiting List Liver Transplant Candidates. Transplantation Proceedings, 2005, 37, 3871-3873.	0.6	21
144	Update in the Therapeutic Management of Irritable Bowel Syndrome. Digestive Diseases, 2001, 19, 244-250.	1.9	9